

### **CURRENT REPORT 27/2023**

May 25<sup>th</sup>, 2023

# Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("**Company**") hereby informs that the Company received a notification prepared in accordance with Article 19.1 of MAR from Mr Hendrik Nogai – Member of the Management Board as from the person discharging managerial responsibilities in the Company due to the implementation of a non-diluting incentive program about which the Company informed in the current reports No. 10/2021 of April 20th, 2021 and No. 14/2021 of May 17th, 2021. The notification is attached to this report.

#### Legal basis: Art. 19.3 of MAR

#### **Representatives of the Company:**

- Paweł Przewięźlikowski President of the Management Board
- Krzysztof Brzózka Vice President of the Management Board

## Notification on transaction/transactions\* referred to

### in Article 19(1) of MAR

1	Data of the person discharging managerial responsibilities / person closely associated with such person			
a)	Entity name/Last name	Hendrik Nogai		
2	Reason for submitting the notification			
a)	Job title/status	Chief Medical Officer		
b)	Original notification / change	Original notification		
3	Data of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Entity name	Ryvu Therapeutics S.A.	Ryvu Therapeutics S.A.	
b)	LEI	2594003WO9Q9HHAFL031		
4		ction: please fill in this field for (i) each instrument type; (ii) each ) each date; and (iv) each trading venue		
a)	Description of the financial instrument, instrument type Identification code	Shares PLSELVT00013		
b)	Transaction type	Receiving a donation		
c)	Price and volume	Price	Volume	
d)	Aggregate information - Total volume - Price	0,19 PLN	9000 9000 0,19 PLN	
e)	Transaction date	2023-05-24		
f)	Trading venue	Out of trading		

\* Delete as appropriate